Akero Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
719
across all filing types
Latest filing
2026-02-17
Major Shareholding Noti…
Country
US
United States of America
Listing
US
AKRO
Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-10 | English | |
| 15-12G | 2025-12-19 | English | |
| Delisting Announcement 2025 | 2025-12-09 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 31561392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31561364 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31561429 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 31561437 | SCHEDULE 13G/A Filing | 2026-02-10 | English | ||
|
2025
11 filings
| |||||
| 13120288 | 15-12G | 2025-12-19 | English | ||
| 13120289 | Delisting Announcement 2025 | 2025-12-09 | English | ||
| 13120292 | 4 | 2025-12-09 | English | ||
| 13120291 | 4 | 2025-12-09 | English | ||
| 13120293 | 4 | 2025-12-09 | English | ||
| 13120294 | 4 | 2025-12-09 | English | ||
| 13120295 | 4 | 2025-12-09 | English | ||
| 13120296 | 4 | 2025-12-09 | English | ||
| 13120297 | 4 | 2025-12-09 | English | ||
| 13120298 | 4 | 2025-12-09 | English | ||
| 13120299 | 4 | 2025-12-09 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
MyndTec Inc.
Develops neurotechnology products for improving function in…
|
MYTC | CA | Professional, scientific and te… |
|
N4 PHARMA PLC
Develops a silica nanoparticle delivery system for nucleic …
|
N4P | GB | Professional, scientific and te… |
|
NanHua Bio-medicine CO.,Ltd．
Develops cell-based therapies, regenerative medicine, and s…
|
000504 | CN | Professional, scientific and te… |
|
Nanjing Leads Biolabs Co., Ltd.
Clinical-stage biotech discovering and developing innovativ…
|
9887 | HK | Professional, scientific and te… |
|
NanoGroup S.A.
Develops nanotechnology-based medical solutions for oncolog…
|
NNG | PL | Professional, scientific and te… |
|
NANO MRNA Co.,Ltd.
Biotechnology firm creating and out-licensing IP for mRNA-b…
|
4571 | JP | Professional, scientific and te… |
|
NanoSphere Health Sciences Inc.
Nano-biotechnology firm creating advanced drug delivery sys…
|
NSHS | CA | Professional, scientific and te… |
|
NANOVIRICIDES, INC.
Clinical-stage biopharma developing broad-spectrum, nanomed…
|
NNVC | US | Professional, scientific and te… |
|
Natcore Technology Inc.
R&D entity using nanotechnology to improve solar cell effic…
|
NTCXF | CA | Professional, scientific and te… |
|
Nautilus Biotechnology, Inc.
Develops a proteome analysis platform to quantify proteins …
|
NAUT | US | Professional, scientific and te… |
Akero Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31200/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31200 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31200 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31200 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31200}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Akero Therapeutics, Inc. (id: 31200)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.